首页> Blood> Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease.

Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease.

导出 OA

翻译打印收藏纠错

第一作者： Martha Q,Lacy

第一单位： Mayo Clinic College of Medicine, Rochester, MN, USA. lacy.martha@mayo.edu

作者： Martha Q,Lacy ^[1] ; Jacob B,Allred ; Morie A,Gertz ; Suzanne R,Hayman ; Kristen Detweiler,Short ; Francis,Buadi ; Angela,Dispenzieri ; Shaji,Kumar ; Philip R,Greipp ; John A,Lust ; Stephen J,Russell ; David,Dingli ; Steven,Zeldenrust ; Rafael,Fonseca ; P Leif,Bergsagel ; Vivek,Roy ; A Keith,Stewart ; Kristina,Laumann ; Sumithra J,Mandrekar ; Craig,Reeder ; S Vincent,Rajkumar ; Joseph R,Mikhael

作者单位： Mayo Clinic College of Medicine, Rochester, MN, USA. lacy.martha@mayo.edu ^[1]

医学主题词投药, 口服(Administration, Oral);成年人(Adult);老年人(Aged);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);硼酸化物(Boronic Acids);地塞米松(Dexamethasone);剂量效应关系, 药物(Dose-Response Relationship, Drug);用药计划表(Drug Administration Schedule);抗药性, 肿瘤(Drug Resistance, Neoplasm);女(雌)性(Female);人类(Humans);男(雄)性(Male);中年人(Middle Aged);多发性骨髓瘤(Multiple Myeloma);吡嗪类(Pyrazines);存活率分析(Survival Analysis);沙立度胺(Thalidomide);治疗失败(Treatment Failure);治疗结果(Treatment Outcome)

DOI 10.1182/blood-2011-04-348896

PMID 21690557

发布时间 2025-05-29

基金项目

R01 CA136671/CA/NCI NIH HHS/United States R01 CA136671-04/CA/NCI NIH HHS/United States R01 CA133966/CA/NCI NIH HHS/United States R01 CA133966-04/CA/NCI NIH HHS/United States R01 AG020686-08/AG/NIA NIH HHS/United States R01 AG020686/AG/NIA NIH HHS/United States

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交